Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Intangibles (2021 - 2025)

Historic Intangibles for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $5.5 million.

  • Rhythm Pharmaceuticals' Intangibles fell 1338.45% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 1338.45%. This contributed to the annual value of $6.2 million for FY2024, which is 1215.14% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Intangibles stood at $5.5 million for Q3 2025, which was down 1338.45% from $5.7 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Intangibles high stood at $8.5 million for Q1 2022, and its period low was $4.7 million during Q4 2021.
  • For the 5-year period, Rhythm Pharmaceuticals' Intangibles averaged around $6.6 million, with its median value being $6.6 million (2024).
  • In the last 5 years, Rhythm Pharmaceuticals' Intangibles soared by 7054.0% in 2022 and then tumbled by 1338.45% in 2025.
  • Rhythm Pharmaceuticals' Intangibles (Quarter) stood at $4.7 million in 2021, then skyrocketed by 69.24% to $7.9 million in 2022, then decreased by 10.85% to $7.0 million in 2023, then dropped by 12.15% to $6.2 million in 2024, then decreased by 10.38% to $5.5 million in 2025.
  • Its last three reported values are $5.5 million in Q3 2025, $5.7 million for Q2 2025, and $6.0 million during Q1 2025.